Refractory Adult T-Cell Leukemia/Lymphoma

2 clinical trials · Condition

Record	Firm	Date
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma (NCT04848064)	John Reneau	2022-05-06
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553)	Mayo Clinic	2017-05-17

Every clearance here is in the API, with alerts when new ones post.